Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670667 · ClinicalTrials.gov registry record
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,132
- Enrollment target
NCT03670667: Completed study, sponsored by Bristol-Myers Squibb.
NCT03670667 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,132 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03670667 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,132 participants
- Enrollment target
Study Summary
An observational study to determine the risk of cancer associated with the use of abatacept and other biologic agents among rheumatoid arthritis patients
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,132 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2019-03-29 |
What the finished NCT03670667 record still lists
NCT03670667 is an observational study that tracks outcomes without assigning an intervention. Its 1,132 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03670667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03670667 about?
NCT03670667 is a clinical study titled "A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents". An observational study to determine the risk of cancer associated with the use of abatacept and other biologic agents among rheumatoid arthritis patients
What is the current status of trial NCT03670667?
This trial is currently completed. The enrollment target is 1,132 participants. The study started on 2017-02-22. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03670667?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03670667?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI